Heparanase induces tissue factor expression in vascular endothelial and cancer cells

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2443-2451

  Nadir, Y ^a,b   Brenner, B ^b   Zetser, A ^a   Ilan, N ^a   Shafat, I ^a   Zcharia, E ^c   Goldshmidt, O ^a   Vlodavsky, Israel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Endothelial cells; Heparanase; Tissue factor; Tumor

Indexed keywords

COMPLEMENTARY DNA; HEPARANASE; SYNAPTOPHYSIN; THROMBOPLASTIN;

ACUTE LEUKEMIA; ANIMAL CELL; ARTICLE; BLAST CELL; BLOOD CLOTTING; CANCER CELL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

BLOOD COAGULATION; CELL LINE, TUMOR; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, LEUKEMIC; HEPARIN LYASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; NEOPLASM INVASIVENESS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THROMBOPLASTIN;

EID: 33750075728     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02212.x     Document Type: Article

References (53)

1. Vu TH, Werb Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 2000; 14: 2123-33.
2. Freeman C, Parish CR. Human platelet heparanase: Purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-50.
3. Pikas DS, Li J-P, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-7.
4. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-7.
5. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL. Heparan sulfate degradation: Relation to tumor invasion and metastatic properties of Mouse B 16 Melanoma sublines. Science 1983; 220: 611-3.
6. Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984; 259: 2283-90.
7. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V. Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relation to tumor cell metastasis. Cancer Res 1983; 43: 2704-11.
8. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, Vlodavsky I. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 1985; 76: 1306-13.
9. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001; 7: 1299-305.
10. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61: 4655-9.
11. Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, Wittekind C, Caca K. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 1270-5.
12. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95: 295-301.
13. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA, Xu X. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002; 132: 326-33.
14. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujikara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N, Haisa M. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 2003; 83: 613-22.
15. Kelly T, Miao H-Q, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003; 63: 8749-56.
16. Sinnappah-Kang ND, Kaiser AJ, Blust BE, Mrak RE, Marchetti D. Heparanase, TrkC and p75NTR: Their functional involvement in human medulloblastoma cell invasion. Int J Oncol 2005; 27: 617-26.
17. Maxhimer JB, Pesce CE, Stewart RA, Gattuso P, Prinz RA, Xu X. Ductal carcinoma in situ of the breast and heparanase-1 expression: A molecular explanation for more aggressive subtypes. J Am Coll Surg 2005; 200: 328-35.
18. Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Heparanase: A key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 2002; 15: 593-8.
19. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol 2003; 14: 1505-10.
20. Sato T, Yamaguchi A, Goi T, Hirano Y, Takeuchi K, Katayama K, Matsukawa S. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J Surg Oncol 2004; 87: 174-81.
21. Watanabe M, Aoki Y, Kase H, Tanaka K. Heparanase expression and angiogenesis in endometrial cancer. Gynecol Obstet Invest 2003; 56: 77-82.
22. Elkin M, Ilan N, Ishai-Michaeli R, Friedman Y, Papo O, Pecker I, Vlodavsky I. Heparanase as mediator of angiogenesis: Mode of action. FASEB J 2001; 15: 1661-3.
23. Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003; 63: 7733-41.
24. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Savid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005; 19: 211-21.
25. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279: 23536-41.
26. Freeman C, Browne AM, Parish CR. Evidence that platelet and tumour heparanases are similar enzymes. Biochem J 1999; 342: 361-8.
27. Ihrcke NS, Parker W, Reissner KJ, Platt JL. Regulation of platelet heparanase during inflammation: Role of pH and proteinases. J Cell Physiol 1998; 175: 255-67.
28. De Cicco M. The prothrombotic state in cancer: Pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-96.
29. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56
30. Versteeg HH, Ruf W. Emerging insight in tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32: 24-32.
31. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Parish CR. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39: 15659-67.
32. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces VEGF expression: Correlation with p38 phosphorylation levels and Src activation. Cancer Research 2006; 66: 1455-63.
33. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117: 2249-58.
34. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkuhler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004; 43: 1862-73.
35. Vlodavsky I. Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. In: Bonifacino JS, Hartford JB, Lippincott-Schwartz J, Yamada KM, eds. Protocols in Cell Biology Vol. 1, New York: John Wiley & Sons, 1999: 10.14.11-4.
36. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 2003; 308: 885-91.
37. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccoti D, Vlodavsky I, Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005; 280: 20457-66.
38. Shafat I, Zcharia E, Nisman B, Nadir Y, Nakhoul F, Vlodavsky I, Ilan N. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun 2006; 341: 958-63.
39. Goldshmidt O, Zcharia E, Cohen M, Aingom H, Cohen I, Nadar L, Katz BZ, Geiger B, Vlodavsky I. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015-25.
40. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, Alon R, Lider O. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172: 5185-93.
41. Zcharia E, Metzger S, Chajek-Shaull T, Aingorn H, Elkin M, Friedmann Y, Weinstein T, Li JP, Lindahl U, Vlodavsky I. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-63.
42. Goldshmidt O, Zcharia E, Aingorn H, Guatta-Rangini Z, Atzman R, Michal I, Pecker I, Mitrani E, Vlodavsky I. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. J Biol Chem 2001; 276: 29178-87.
43. Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, Schirrmacher V, Mitrani E, Vlodavsky I. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 2002; 99: 10031-6.
44. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737-43.
45. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-27.
46. Vreys V, Delande N, Zhang Z, Coomans C, Roebroek A, Durr J, David G. Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J Biol Chem 2005; 280: 33141-8.
47. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96: 8663-8.
48. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
49. Lopez-Pedrera C, Buendia P, Cuadrado MJ, Seindones E, Aguirre MA, Barbarroja N, Montiel-Duarte C, Torres A, Khamashta M, Velasco F. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-11.
50. Ohsawa M, Koyama T, Nara N, Hirosawa S. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Thromb Res 2003; 112: 313-20.
51. Yahalom J, Eldor A, Fuks Z, Vlodavsky I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 1984; 74: 1842-9.
52. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
53. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.